e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Healthcare organisation and appropriateness in lung disorders
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Olga Shtepa (Dnipropetrovsk, Ukraine), Olga Shtepa, Tetyana Pertseva, Tetyana Kireyeva
Source:
International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Session:
Healthcare organisation and appropriateness in lung disorders
Session type:
Thematic Poster Session
Number:
706
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Olga Shtepa (Dnipropetrovsk, Ukraine), Olga Shtepa, Tetyana Pertseva, Tetyana Kireyeva. Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP). Eur Respir J 2015; 46: Suppl. 59, 706
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)?
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015
Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI)
Source: Annual Congress 2013 –Lung infections: a clinical point of view
Year: 2013
Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 805s
Year: 2006
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Community acquired pneumonia (CAP) mortality and biomarkers
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021
Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005
Cardiac diseases in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012
The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept